{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T02:08:52Z","timestamp":1767665332988,"version":"build-2065373602"},"reference-count":31,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2012,1,6]],"date-time":"2012-01-06T00:00:00Z","timestamp":1325808000000},"content-version":"vor","delay-in-days":1253,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2008,8]]},"abstract":"<jats:p><jats:bold>Objective.<\/jats:bold> To review the effectiveness and safety of rifaximin for the treatment of hepatic encephalopathy.<\/jats:p><jats:p><jats:bold>Methods.<\/jats:bold> A literature search was conducted of MEDLINE (1966\u2010September 2007), the Cochrane Database of Systematic Reviews (1995\u20132007), and the Cochrane Hepato\u2010Biliary Group Reviews (2003\u20132007). English\u2010language articles identified from the data sources were evaluated. All available studies were reviewed, including placebo\u2010controlled, treatment comparison, and open label.<\/jats:p><jats:p><jats:bold>Results.<\/jats:bold> Rifaximin was effective in improving behavioral, laboratory, mental status, and intellectual abnormalities associated with hepatic encephalopathy. Some studies demonstrated superior and more rapid improvement in signs or symptoms of encephalopathy during treatment with rifaximin compared with nonabsorbable disaccharides (lactulose, lactitol). Patients treated with rifaximin also required less hospitalization, had shorter duration of hospitalization, and lower hospital charges compared with lactulose\u2010treated patients. Adverse effects of rifaximin were mostly minor gastrointestinal complaints; however, rifaximin was better tolerated than other pharmacologic treatments.<\/jats:p><jats:p><jats:bold>Conclusion.<\/jats:bold> Rifaximin was at least equally effective as and in some studies superior to nonabsorbable disaccharides and antimicrobials in relieving signs or symptoms observed in patients with mild\u2010to\u2010moderately severe hepatic encephalopathy. Future clinical trials should focus on using standardized methods of evaluating mental status and limiting enrollment to patients with mild\u2010to\u2010moderate, episodic, persistent, or minimal hepatic encephalopathy. Well\u2010designed studies are needed to fully delineate the efficacy of rifaximin and other pharmacologic treatments for patients with hepatic encephalopathy.<\/jats:p>","DOI":"10.1592\/phco.28.8.1019","type":"journal-article","created":{"date-parts":[[2008,7,25]],"date-time":"2008-07-25T12:56:02Z","timestamp":1216990562000},"page":"1019-1032","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Rifaximin for the Treatment of Hepatic Encephalopathy"],"prefix":"10.1002","volume":"28","author":[{"given":"Kenneth R.","family":"Lawrence","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline A.","family":"Klee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,6]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"431","volume-title":"Hepatology: a textbook of liver disease","author":"Weissenborn K","year":"2003"},{"issue":"1","key":"e_1_2_1_3_2","doi-asserted-by":"crossref","first-page":"S171","DOI":"10.1016\/S0168-8278(00)80424-9","article-title":"Complications of cirrhosis. III. Hepatic encephalopathy","volume":"32","author":"Butterworth RE","year":"2000","journal-title":"J Hepatol"},{"key":"e_1_2_1_4_2","first-page":"595","volume-title":"Schiff's diseases of the liver","author":"Cordoba J","year":"2003"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1006\/phrs.1997.0198"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.31250"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01072921"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.03964.x"},{"key":"e_1_2_1_9_2","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0016-5085(77)80135-2","article-title":"Comparison of lactulose and neomycin in the treatment of chronic portal\u2010systemic encephalopathy: a double\u2010blind controlled trial","volume":"72","author":"Conn HO","year":"1977","journal-title":"Gastroenterology"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(99)80144-5"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38048.506134.EE"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)70239-7"},{"key":"e_1_2_1_13_2","unstructured":"U.S. Food and Drug Administration.List of orphan products designation and approvals as of October 3 2007. Available fromhttp:www.fda.govohrmsdocketsdailys00mar00030100lst0094.pdf. Accessed October 20 2007."},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1086\/499950"},{"volume-title":"Formenti (rifaximina) package insert","year":"1997","author":"Rugby.","key":"e_1_2_1_15_2"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007999509111552"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200012020-00012"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.curtheres.2004.10.002"},{"key":"e_1_2_1_19_2","first-page":"387","article-title":"A non\u2010absorbable rifamycin for treatment of hepatic encephalopathy","volume":"11","author":"Testa R","year":"1985","journal-title":"Drugs Exp Clin Res"},{"key":"e_1_2_1_20_2","first-page":"961","article-title":"Treatment of hepatic encephalopathy with L\/105, a new non\u2010absorbable rifamycin","volume":"10","author":"Eftimiadi C","year":"1984","journal-title":"Drugs Exp Clin Res"},{"key":"e_1_2_1_21_2","first-page":"668","article-title":"Rifaximin in collateral treatment of portal systemic encephalopathy: a preliminary report","volume":"36","author":"DeMarco F","year":"1984","journal-title":"Curr Ther Res Clin Exp"},{"key":"e_1_2_1_22_2","first-page":"175","article-title":"Rifaximin versus neomycin on hyperammonemia in chronic portal systemic encephalopathy of cirrhosis: a double\u2010blind, randomized trial","volume":"23","author":"Pedretti G","year":"1991","journal-title":"Ital J Gastroenterol"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0011-393X(05)80433-3"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007999709113333"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007999309111539"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0011-393X(05)80681-2"},{"key":"e_1_2_1_27_2","first-page":"4","article-title":"Treatment of hepatic encephalopathy with rifaximin: double\u2010blind, double\u2010dummy, study versus lactulose","volume":"4","author":"Massa R","year":"1993","journal-title":"Eur J Clin Res"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(02)00350-1"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2005.46.3.399"},{"key":"e_1_2_1_30_2","unstructured":"BassNM AhmedA JohnsonL GardnerJD.Rifaximin treatment is beneficial for mild hepatic encephalopathy. Presented at the 55th annual meeting of the American Association for the Study of Liver Diseases Boston MA October 29-November 2 2004."},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-006-9442-4"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2006.10.107"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.28.8.1019","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.28.8.1019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:46:32Z","timestamp":1761047192000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.28.8.1019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["10.1592\/phco.28.8.1019"],"URL":"https:\/\/doi.org\/10.1592\/phco.28.8.1019","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[2008,8]]},"assertion":[{"value":"2012-01-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}